Global Startups Insights
Lets your startup
Funding News, Washington

BrainChild Bio Raises $116M Series A to Advance CAR T Cancer Therapies

September 8, 2026
By
Loren Baker
BrainChild Bio Raises $116M Series A to Advance CAR T Cancer Therapies

BrainChild Bio, a Seattle-based biotechnology company developing CAR T cell therapies for tumors in the central nervous system, has raised $116 million in Series A funding.

The financing was led by an undisclosed private family fund and foundation. Existing investor Seattle Children’s and new investor WRF Capital also participated in the round.

BrainChild Bio plans to use the funding to advance its lead therapy, BCB-276, through the ILLUMINATE Phase 2 clinical trial. The trial is evaluating the therapy as a potential treatment for diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor that primarily affects children.

The company will also use part of the funding to continue developing BCB-214, a triple-targeting CAR T cell therapy being prepared for initial clinical testing in glioblastoma.

Founded as a clinical-stage biotechnology company, BrainChild Bio is focused on developing new CAR T cell treatments for tumors affecting the central nervous system. Its technology combines synthetic biology approaches, including multiplex targeting, with a specialized method of delivering CAR T cells directly into the cerebrospinal fluid.

“Our path to building BrainChild Bio has led us to secure the support of a unique and committed syndicate of investors who share our mission to prioritize therapeutic innovation for children with cancer, while also rapidly advancing new science that can change the course of brain cancers for a wider population,” said Steven Brugger, Chief Executive Office of BrainChild Bio. “We believe the time is right to show the breakthrough potential for our CAR T cell therapeutic approach with BCB-276 for DIPG which is a devastating pediatric brain cancer, as well as accelerate our efforts to advance other CAR T cell therapies for pediatric and adult brain tumors.”

“This financing enables us to chart our path forward to serve the children and families afflicted with devastating brain tumors and represents a new paradigm for treating CNS brain tumors in children and adults,” stated Michael Jensen, MD, Founder and Chief Scientific Officer of BrainChild Bio. “Our team at BrainChild Bio is steadfast in its commitment to harness CAR T cell technology in CNS tumors and we are uniquely positioned to do so.”

The company’s delivery approach uses an implanted reservoir-catheter, which is designed to allow repeated infusions of CAR T cells. BrainChild Bio believes this could help the therapies reach tumors more effectively while potentially reducing unwanted effects elsewhere in the body.

Its lead program, BCB-276, targets B7-H3, an immune checkpoint found on tumor cells. BrainChild Bio has advanced the therapy into a registration-stage development program for DIPG and has established manufacturing, quality and regulatory infrastructure to support the program.

DIPG is a particularly difficult cancer to treat because of its location in the brainstem, its infiltrative growth and the blood-brain barrier, which can limit the ability of conventional treatments to reach the tumor.

BrainChild Bio’s approach is designed to overcome some of these challenges by delivering CAR T cells directly into the cerebrospinal fluid surrounding the tumor. The company is also exploring repeated dosing to potentially provide longer-lasting treatment effects.

Led by CEO Steven Brugger, BrainChild Bio was built around technology originally developed at Seattle Children’s and licensed exclusively to the company.

With the new $116 million financing, BrainChild Bio aims to advance its lead DIPG program through Phase 2 development while expanding its pipeline of CAR T cell therapies for pediatric and adult central nervous system cancers.

Recommended Stories for You